Hanmi Pharm. Co., Ltd. announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'. R&D-oriented pharmaceutical company, Hanmi Pharmaceutical's Rosuzet is a dyslipidemia medicine, is a single-pill combination of two different active ingredients: rosuvastatin and ezetimibe, and is a blockbuster product that records prescription sales in Korea of more than one hundred million dollars.

The result of a large randomized trial comparing Rosuzet and rosuvastatin monotherapy in 3,780 patients with arteriosclerotic cardiovascular disease (ASCVD) was published in The Lancet(IF 202.731) in August, 2022. This study was named 'RACING'. A sub-analysis of the diabetes mellitus (DM) cohort of the RACING study was published in the European Heart Journal(IF 35.855) in December, 2022.

This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy(Rosuzet) versus high-intensity statin monotherapy among 1398 patients with DM and ASCVD.